EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, 4D Molecular Therapeutics's Enterprise Value is $1,094.39 Mil.
4D Molecular Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-78.56 Mil. Therefore, 4D Molecular Therapeutics's EV-to-FCF for today is -13.93.
The historical rank and industry rank for 4D Molecular Therapeutics's EV-to-FCF or its related term are showing as below:
FDMT'
s EV-to-FCF Range Over the Past 10 Years
Min: -27.55 Med: -4.99 Max: 0.15
Current: -13.93
During the past 7 years, the highest EV-to-FCF of 4D Molecular Therapeutics was 0.15. The lowest was -27.55. And the median was -4.99.
FDMT's EV-to-FCF is ranked worse than 100% of 382
companies
in the Biotechnology industry
Industry Median: 5.84
vs FDMT: -13.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of 4D Molecular Therapeutics's EV-to-FCF
For the Biotechnology subindustry, 4D Molecular Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4D Molecular Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's EV-to-FCF falls into.
4D Molecular Therapeutics's current Enterprise Value is $1,094.39 Mil.
4D Molecular Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
4D Molecular Therapeutics's PE Ratio for today is calculated as:
4D Molecular Therapeutics's share price for today is $26.80.
4D Molecular Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
4D Molecular Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of 4D Molecular Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
4D Molecular Therapeutics (4D Molecular Therapeutics) Business Description
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FDMT has been successfully added to your 